FDA’s approval of Otarmeni, the first gene therapy for hereditary deafness

In a lab room, a toddler, deaf from birth, sits while a tone plays. There’s no reaction. His face does not change.

Six weeks later, after a single injection of an experimental gene therapy, the same toddler is back in the same room. The tone plays. The toddler’s head turns toward the sound….